keyword
MENU ▼
Read by QxMD icon Read
search

opicapone

keyword
https://www.readbyqxmd.com/read/27763682/effect-of-opicapone-multiple-dose-regimens-on-levodopa-pharmacokinetics
#1
José-Francisco Rocha, Éric Sicard, Nicolas Fauchoux, Amílcar Falcão, Ana Santos, Ana I Loureiro, Roberto Pinto, Maria João Bonifácio, Teresa Nunes, Luís Almeida, Patrício Soares-da-Silva
AIMS: To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa. METHODS: Two randomized, double blind, sex-balanced, placebo-controlled studies in four groups of 12 or 18 healthy subjects each. In each group, enrolled subjects received a once-daily morning (5, 15 and 30 mg) or evening (5, 15 and 50 mg) administration of OPC or placebo for up to 28 days...
October 20, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27599671/clinical-pharmacology-review-of-opicapone-for-the-treatment-of-parkinson-s-disease
#2
Margherita Fabbri, Mario M Rosa, Joaquim J Ferreira
Two catechol-O-methyl transferase inhibitors are currently used as add-on therapy to levodopa for the amelioration of end-of-dose motor fluctuations in Parkinson's disease patients: entacapone, which has moderate efficacy and requires multiple dosing, and tolcapone, which has a poor safety profile. Opicapone (OPC) is a novel, long-acting, peripherally selective, once daily, third-generation catechol-O-methyl transferase inhibitor. Two Phase III clinical trials demonstrated OPC efficacy in reducing OFF-time by an average of about 60 min daily compared with placebo, without increasing ON-time with troublesome dyskinesias, with a good drug safety profile...
October 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27590245/erratum-to-opicapone-a-review-in-parkinson-s-disease
#3
Lesley J Scott
No abstract text is available yet for this article.
October 2016: Drugs
https://www.readbyqxmd.com/read/27498199/opicapone-a-review-in-parkinson-s-disease
#4
Lesley J Scott
Oral opicapone (Ongentys(®)), a potent, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson's disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on those combinations. In 14- to 15-week, double-blind, multinational trials and in 1-year, open-label extension studies in this patient population, opicapone was an effective and generally well tolerated adjunctive therapy to L-Dopa plus a DDCI and other PD therapy...
September 2016: Drugs
https://www.readbyqxmd.com/read/27163503/effect-of-3-single-dose-regimens-of-opicapone-on-levodopa-pharmacokinetics-catechol-o-methyltransferase-activity-and-motor-response-in-patients-with-parkinson-disease
#5
José-Francisco Rocha, Joaquim J Ferreira, Amílcar Falcão, Ana Santos, Roberto Pinto, Teresa Nunes, Luis Almeida, Patrício Soares-da-Silva
This study determined the effects of single doses of opicapone (OPC), a novel third-generation catechol-O-methyltransferase (COMT) inhibitor, on levodopa and 3-O-methyl-levodopa (3-OMD) pharmacokinetics (PK), COMT activity and motor fluctuations in patients with Parkinson disease (PD). Subjects received, in a double-blind manner, 25, 50, and 100 mg OPC or placebo (PLC) in 4 separate treatment periods. The washout period between doses was at least 10 days. During each period, the OPC/PLC capsules were to be coadministered with the morning dose of 100/25 mg levodopa/carbidopa (LC) or levodopa/benserazide (LB) on day 3...
May 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27138028/opicapone-pharmacokinetics-and-pharmacodynamics-comparison-between-healthy-japanese-and-matched-white-subjects
#6
Amílcar Falcão, José Francisco Rocha, Ana Santos, Teresa Nunes, Patrício Soares-da-Silva
Opicapone (OPC) is a novel third-generation catechol-O-methyltransferase (COMT) inhibitor. This randomized, double-blind, parallel, placebo-controlled and multiple ascending dose study in 3 sequential groups of up to 38 (19 Japanese plus 19 white subjects) aimed to compare the pharmacokinetics (PK) and pharmacodynamics (PD; COMT activity) of opicapone between healthy Japanese and matched white subjects. Enrolled subjects received a once-daily morning administration of OPC (5, 25, or 50 mg) or placebo for 10 days, with plasma and urine concentrations of opicapone and its metabolites measured up to 144 hours postdose, including S-COMT activity...
March 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27137718/evaluation-of-opicapone-on-cardiac-repolarization-in-a-thorough-qt-qtc-study
#7
Roberto Pinto, Philippe l'Hostis, Alain Patat, Marie-Claude Homery, Amílcar Falcão, Teresa Nunes, José-Francisco Rocha, Patrício Soares-da-Silva
Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor for use as adjunctive therapy in levodopa-treated Parkinson's disease patients, was investigated on cardiac repolarization in healthy adult volunteers. This was a single-center, randomized, double-blind, placebo-controlled, open-label active-controlled, 4-period crossover study conducted in 64 subjects. In each period, subjects received a single oral dose of 50 mg opicapone, 800 mg opicapone, placebo, or 400 mg moxifloxacin and 24-hour 12-lead Holter monitoring was performed on day -1 (baseline) and after each single dose...
November 2015: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/26725545/opicapone-for-motor-fluctuations-in-parkinson-s-disease
#8
David Devos, Caroline Moreau
No abstract text is available yet for this article.
December 22, 2015: Lancet Neurology
https://www.readbyqxmd.com/read/26725544/opicapone-as-an-adjunct-to-levodopa-in-patients-with-parkinson-s-disease-and-end-of-dose-motor-fluctuations-a-randomised-double-blind-controlled-trial
#9
Joaquim J Ferreira, Andrew Lees, José-Francisco Rocha, Werner Poewe, Olivier Rascol, Patrício Soares-da-Silva
BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. We aimed to assess the safety and efficacy of opicapone as an adjunct to levodopa compared with placebo or entacapone in patients with Parkinson's disease and motor fluctuations. METHODS: We did a randomised, double-blind, placebo-controlled and active-controlled trial of opicapone as an adjunct to levodopa in patients with Parkinson's disease with end-of-dose motor fluctuations...
December 22, 2015: Lancet Neurology
https://www.readbyqxmd.com/read/26293004/new-treatments-for-levodopa-induced-motor-complications
#10
REVIEW
Olivier Rascol, Santiago Perez-Lloret, Joaquim J Ferreira
Levodopa (l-dopa)-induced motor complications, including motor fluctuations and dyskinesia, affect almost all patients with Parkinson's disease (PD) at some point during the disease course, with relevant implications in global health status. Various dopaminergic and nondopaminergic pharmacological approaches as well as more invasive strategies including devices and functional surgery are available to manage such complications. In spite of undisputable improvements during the last decades, many patients remain significantly disabled, and a fully satisfying management of l-dopa-induced motor complications is still an important unmet need of PD therapy...
September 15, 2015: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/26147707/development-of-a-liquid-chromatography-assay-for-the-determination-of-opicapone-and-bia-9-1079-in-rat-matrices
#11
Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Patrício Soares-da-Silva, Amílcar Falcão
Opicapone is a novel potent, reversible and purely peripheral third generation catechol-O-methyltransferase inhibitor, currently under clinical trials as an adjunct to levodopa therapy for Parkinson's disease. To support additional nonclinical pharmacokinetic studies, a novel high-performance liquid chromatographic method coupled to a diode array detector (HPLC-DAD) to quantify opicapone and its active metabolite (BIA 9-1079) in rat plasma and tissues (liver and kidney) is herein reported. The analytes were extracted from rat samples through a deproteinization followed by liquid-liquid extraction...
March 2016: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/25649051/effect-of-opicapone-on-levodopa-pharmacokinetics-catechol-o-methyltransferase-activity-and-motor-fluctuations-in-patients-with-parkinson-s-disease
#12
RANDOMIZED CONTROLLED TRIAL
J J Ferreira, J-F Rocha, A Falcão, A Santos, R Pinto, T Nunes, P Soares-da-Silva
BACKGROUND AND PURPOSE: Opicapone (OPC) is a novel third generation catechol-O-methyltransferase (COMT) inhibitor that enhances levodopa availability. This study investigated the effects of OPC in comparison with placebo on levodopa pharmacokinetics, tolerability and safety, COMT activity and motor response to levodopa in Parkinson's disease (PD) patients with motor fluctuations. METHODS: This was a randomized, multicentre, double-blind and placebo-controlled study in four parallel groups of PD patients treated with standard-release 100/25 mg levodopa/carbidopa or levodopa/benserazide and with motor fluctuations (wearing-OFF phenomenon)...
May 2015: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/25409768/pharmacological-profile-of-opicapone-a-third-generation-nitrocatechol-catechol-o-methyl-transferase-inhibitor-in-the-rat
#13
M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright, P Soares-da-Silva
BACKGROUND AND PURPOSE: Catechol-O-methyltransferase (COMT) is an important target in the levodopa treatment of Parkinson's disease; however, the inhibitors available have problems, and not all patients benefit from their efficacy. Opicapone was developed to overcome those limitations. In this study, opicapone's pharmacological properties were evaluated as well as its potential cytotoxic effects. EXPERIMENTAL APPROACH: The pharmacodynamic effects of opicapone were explored by evaluating rat COMT activity and levodopa pharmacokinetics, in the periphery through microdialysis and in whole brain...
April 2015: British Journal of Pharmacology
https://www.readbyqxmd.com/read/24925090/effect-of-opicapone-and-entacapone-upon-levodopa-pharmacokinetics-during-three-daily-levodopa-administrations
#14
RANDOMIZED CONTROLLED TRIAL
José-Francisco Rocha, Amílcar Falcão, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Lyndon C Wright, Manuel Vaz-da-Silva, Patrício Soares-da-Silva
BACKGROUND AND OBJECTIVES: Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. METHODS: A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study...
September 2014: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/24271646/effect-of-moderate-liver-impairment-on-the-pharmacokinetics-of-opicapone
#15
José Francisco Rocha, Ana Santos, Amílcar Falcão, Nelson Lopes, Teresa Nunes, Roberto Pinto, Patrício Soares-da-Silva
PURPOSE: Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. The purpose of this study was to evaluate the effect of moderate liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD; effect on COMT activity) of OPC. METHODS: An open-label, parallel-group study in patients (n = 8) with moderate liver impairment (Child-Pugh category B, score of 7 to 9) and matched healthy subjects (n = 8, control) with normal liver function...
March 2014: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/24148813/brain-and-peripheral-pharmacokinetics-of-levodopa-in-the-cynomolgus-monkey-following-administration-of-opicapone-a-third-generation-nitrocatechol-comt-inhibitor
#16
M J Bonifácio, J S Sutcliffe, L Torrão, L C Wright, P Soares-da-Silva
OBJECTIVE: The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. METHODS: Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days...
February 2014: Neuropharmacology
https://www.readbyqxmd.com/read/23476919/an-hplc-dad-method-for-the-simultaneous-quantification-of-opicapone-bia-9-1067-and-its-active-metabolite-in-human-plasma
#17
Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Patrício Soares-da-Silva, Amílcar Falcão
Opicapone (BIA 9-1067) is a novel catechol-O-methyltransferase inhibitor presently under clinical development as an adjuvant in the pharmacotherapy of Parkinson's disease. This report describes the development and validation of a bioanalytical assay for the simultaneous quantification of opicapone and its active metabolite (BIA 9-1079) in human plasma. The method herein reported is based on high-performance liquid chromatography coupled with diode-array detection (HPLC-DAD) and the sample preparation consists of a plasma protein precipitation step followed by liquid-liquid extraction...
April 21, 2013: Analyst
https://www.readbyqxmd.com/read/23336248/opicapone-a-short-lived-and-very-long-acting-novel-catechol-o-methyltransferase-inhibitor-following-multiple-dose-administration-in-healthy-subjects
#18
RANDOMIZED CONTROLLED TRIAL
José Francisco Rocha, Luis Almeida, Amílcar Falcão, P Nuno Palma, Ana I Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C Wright, Teresa Nunes, Patrício Soares-da-Silva
AIMS: The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity following repeated doses of opicapone. METHODS: This randomized, placebo-controlled, double-blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30 mg for 8 days. RESULTS: Opicapone was well tolerated. Its systemic exposure increased in an approximately dose-proportional manner with an apparent terminal half-life of 1...
November 2013: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/23248072/pharmacokinetics-pharmacodynamics-and-tolerability-of-opicapone-a-novel-catechol-o-methyltransferase-inhibitor-in-healthy-subjects-prediction-of-slow-enzyme-inhibitor-complex-dissociation-of-a-short-living-and-very-long-acting-inhibitor
#19
RANDOMIZED CONTROLLED TRIAL
Luis Almeida, José Francisco Rocha, Amílcar Falcão, P Nuno Palma, Ana I Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C Wright, Teresa Nunes, Patrício Soares-da-Silva
BACKGROUND AND OBJECTIVES: Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. METHODS: Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design...
February 2013: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/22123108/bioanalytical-chromatographic-methods-for-the-determination-of-catechol-o-methyltransferase-inhibitors-in-rodents-and-human-samples-a-review
#20
REVIEW
Daniela Gonçalves, Gilberto Alves, Patrício Soares-da-Silva, Amílcar Falcão
In the past years, it has been recognised that the levodopa therapy may be improved with therapeutic regimens including a catechol-O-methyltransferase (COMT) inhibitor. At the present time, tolcapone and entacapone are the only two COMT inhibitors available in the market. However, further COMT inhibitors are under development for Parkinson's disease, namely nebicapone and opicapone (formerly known as BIA 9-1067). In addition, the nitecapone, another well-known COMT inhibitor, is also in preclinical development but for neuropathic pain...
January 13, 2012: Analytica Chimica Acta
keyword
keyword
118635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"